Even as demand for blockbuster GLP-1 weight-loss drugs explodes, Jefferson Health’s own employees are mostly watching from the sidelines. The system’s chief executive says Jefferson would like to cover the medications for its workforce, but the tab is simply too steep as pharmacy costs climb and red ink spreads.
Joseph G. Cacchione told NBC News that “the system wants to pay for them. We just can’t afford to pay for them right now,” describing a tug-of-war between intense employee demand and the health system’s shaky finances. Jefferson’s combined university and health system reported a roughly $195.5 million operating loss for fiscal 2025, most of it tied to a nearly $170 million deficit in its insurance business, according to The Philadelphia Inquirer. That shortfall has Jefferson leaders rethinking what the employer health plan will cover and when.
Sticker Shock: What Employers Would Pay
Brand-name GLP-1 drugs come with four-digit list prices that can make even big employers swallow hard. Eli Lilly’s Zepbound carries a list price near $1,086 per month, and Novo Nordisk’s Wegovy has been priced above $1,300, according to the Washington Post. Novo Nordisk has announced it will cut Wegovy and Ozempic list prices to $675 a month starting Jan. 1, 2027, a move the company detailed in a statement on Novo Nordisk’s website.
Even with discounts factored in, the net cost can stay hefty. Modeling by Blue Cross Blue Shield suggests employers could pay roughly $617 to $766 a month per covered worker using the drugs, a range big enough to nudge premiums higher if coverage expands widely.
How Employers Are Responding
Large employers are not rushing in without guardrails. The 2025 Employer Health Benefits Survey from the Kaiser Family Foundation found that about 19% of firms with 200 or more workers covered GLP-1s specifically for weight loss, and roughly one-third of those that do cover them make employees complete diet or lifestyle programs before they can fill prescriptions.
Jefferson’s insurance arm has adopted that playbook. It began requiring members to go through diet or lifestyle programs before covering GLP-1 therapy, a move Cacchione told NBC News saved about $20 million. Other employers are leaning on prior authorization rules, step therapy and tight eligibility criteria to keep usage in check.
Price Cuts May Not Be a Panacea
Headline-grabbing list-price cuts will help some patients who pay cash, but consultants caution that employers may not feel much immediate relief. Willis Towers Watson notes that rebates, existing contracts and already negotiated net prices can blunt the impact of list-price reductions for self-funded plans. In other words, even if the sticker price drops, the actual bill for employer plans might not fall nearly as fast.
That helps explain why Jefferson and many other employers are wary about opening the floodgates on coverage, even as the drugs continue to post strong clinical results.
Local Fallout: Jobs and Budgets
The financial squeeze is already hitting close to home. Jefferson has announced workforce reductions affecting roughly 600 to 700 positions across its combined university and health system as it tries to close the gap created in part by fast-rising pharmacy claims, according to LehighValleyNews. Executives describe the cuts as part of a multi-year effort to stabilize operations while juggling benefit design, coverage decisions and patient care priorities.
Independent reviewers say there is a core tension here. GLP-1 therapies provide meaningful clinical benefits and can be cost-effective for individual patients, yet the Institute for Clinical and Economic Review has warned that expanded coverage at current volumes could strain health care budgets, according to ICER. For Philadelphia-area employers, workers and benefits managers, the next several weeks - including any new pricing moves from manufacturers and possible federal policy shifts - will help determine whether coverage can broaden without blowing up the bottom line.
